Post-earnings recap
Reported
Thu, Feb 10, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bio Rad Laboratories reported a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 1.89%, likely due to the absence of revenue figures and guidance, which may have left investors uncertain about future performance. The cautious tone from management regarding supply chain issues could also be contributing to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.21 | N/A | +11.85% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautiously optimistic outlook, emphasizing their commitment to navigating supply chain challenges. They highlighted strong product performance as a key driver.
Management highlighted strong performance in key product lines.
They noted ongoing challenges in the supply chain but remain focused on growth.
Future investments are aimed at expanding market presence.